S'abonner

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study - 29/12/12

Doi : 10.1016/S1470-2045(12)70489-8 
Pasi A Jänne, DrMD a, , Alice T Shaw, MD b, José Rodrigues Pereira, MD c, Gaëlle Jeannin, MD d, Johan Vansteenkiste, ProfMD e, Carlos Barrios, MD f, Fabio Andre Franke, MD g, Lynda Grinsted, MSc h, Victoria Zazulina, MD h, Paul Smith, PhD h, Ian Smith, MD h, Lucio Crinò, ProfMD i
a Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA 
b Massachusetts General Hospital Cancer Center, Boston, MA, USA 
c Instituto Brasileiro de Cancerologia Torácica, Sao Paulo, Brazil 
d Service de Pneumologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France 
e Respiratory Oncology Unit and Trial Unit, Department of Pneumology, University Hospital Gasthuisberg, Leuven, Belgium 
f PUCRS School of Medicine, Centro de Pesquisa em Oncologia, Porto Alegre, Brazil 
g CACON, Hospital de Caridade de Ijuí, Ijuí, Brazil 
h AstraZeneca UK, Macclesfield, UK 
i Medical Oncology Division, Hospital S Maria della Misericordia, Perugia, Italy 

* Correspondence to: Dr Pasi A Jänne, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

Summary

Background

No targeted therapies are available for KRAS-mutant non-small-cell lung cancer (NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers. We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC.

Methods

Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB–IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0–1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function. Patients were randomly assigned (in a 1:1 ratio) to either oral selumetinib (75 mg twice daily in a 21 day cycle) or placebo; all patients received intravenous docetaxel (75 mg/m2 on day 1 of a 21 day cycle). Randomisation was done with an interactive voice response system and investigators, patients, data analysts, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival, analysed for all patients with confirmed KRAS mutations. This study is registered with ClinicalTrials.gov, number NCT00890825.

Findings

Between April 20, 2009, and June 30, 2010, we randomly assigned 44 patients to receive selumetinib and docetaxel (selumetinib group) and 43 to receive placebo and docetaxel (placebo group). Of these, one patient in the selumetinib group and three in the placebo group were excluded from efficacy analyses because their tumours were not confirmed to be KRAS-mutation positive. Median overall survival was 9·4 months (6·8–13·6) in the selumetinib group and 5·2 months (95% CI 3·8–non-calculable) in the placebo group (hazard ratio [HR] for death 0·80, 80% CI 0·56–1·14; one-sided p=0·21). Median progression-free survival was 5·3 months (4·6–6·4) in the selumetinib group and 2·1 months (95% CI 1·4–3·7) in the placebo group (HR for progression 0·58, 80% CI 0·42–0·79; one-sided p=0·014). 16 (37%) patients in the selumetinib group and none in the placebo group had an objective response (p<0·0001). Adverse events of grade 3 or higher occurred in 36 (82%) patients in the selumetinib group and 28 (67%) patients in the placebo group. The most common grade 3–4 adverse events were neutropenia (29 [67%] of 43 patients in the selumetinib group vs 23 [55%] of 42 patients in the placebo group), febrile neutropenia (eight [18%] of 44 patients in the selumetinib group vs none in the placebo group), dyspnoea (one [2%] of 44 patients in the selumetinib group vs five [12%] of 42 in the placebo group), and asthenia (four [9%] of 44 patients in the selumetinib group vs none in the placebo group).

Interpretation

Selumetinib plus docetaxel has promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC. These findings warrant further clinical investigation of selumetinib plus docetaxel in KRAS-mutant NSCLC.

Funding

AstraZeneca.

Le texte complet de cet article est disponible en PDF.

Plan


© 2013  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 14 - N° 1

P. 38-47 - janvier 2013 Retour au numéro
Article précédent Article précédent
  • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
  • Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg, Claus-Christoph Steffens, Vicente Alonso-Orduña, Christoph Schlichting, Irmarie Reyes-Rivera, Belguendouz Bendahmane, Thierry André, Stefan Kubicka, on behalf of the ML18147 Study Investigators †
| Article suivant Article suivant
  • Intraoperative ultrasound guidance for palpable breast cancer excision (COBALT trial): a multicentre, randomised controlled trial
  • Nicole MA Krekel, Max H Haloua, Alexander MF Lopes Cardozo, Roos H de Wit, Anne Marie Bosch, Louise M de Widt-Levert, Sandra Muller, Henk van der Veen, Elisabeth Bergers, Elly SM de Lange de Klerk, Sybren Meijer, M Petrousjka van den Tol

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.